fbpx
QQQ
+ 3.27
337.97
+ 0.96%
DIA
-0.77
345.89
-0.22%
SPY
+ 0.99
423.32
+ 0.23%
TLT
-1.09
143.40
-0.77%
GLD
-1.00
176.74
-0.57%

MediPharm Posts Q1 2021 Results: What Cannabis Stock Investors Need To Know

May 17, 2021 11:08 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
MediPharm Posts Q1 2021 Results: What Cannabis Stock Investors Need To Know

MediPharm Labs Corp. (TSX:LABS) (OTCQX:MEDIF) (FSE:MLZ) reported Monday its first-quarter revenue amounted to CA$5.49 million ($4.53 million), down by roughly 9% sequentially and 50% year-over-year.

Adjusted EBITDA, a non-IFRS measure, came in negative at roughly CA$6.16 million, representing an improvement from a CA$8.77 million loss in the prior quarter and a loss of CA$5.66 million in the same quarter of 2020.

Greg Hunter, CFO of the Barrie, Ontario-based company, called the quarter a "cross-over period to our future state as the preferred global cannabis API provider to medical and wellness markets."

Q1 2021 Highlights

  • Gross profit was negative at CA$680 000 compared to a negative gross profit of CA$24.7 million in the previous quarter and CA$10.9 million in the same period of 2020.
  • A negative gross margin was 12%, compared to a negative gross margin of 408% in the last three months of 2020 and 98% in the prior year's corresponding quarter.
  • Net loss amounted to approximately CA$13.9 million, after shrinking by 55% sequentially and 37% year-over-year.
  • International sales rose to CA$1.8 million over the last three months of 2020, to CA$2.1 million in the first quarter of 2021.
  • The company achieved more than CA$1.5 million in cost savings.
  • As of March 31, the company had CA$42.1 million in cash and cash equivalents.

"We commenced 2021 focused on establishing our presence as a pharmaceutical company while ramping up and significantly growing our international sales," Hunter added.

In October, MediPharm Labs inked a deal to supply GMP-certified medical cannabis products to German pharmaceutical giant Stada Arzneimittel AG.

Six months later, in April, the company expanded its reach in the German market by signing a two-year supply agreement with the subsidiary of the multi-country medical and recreational cannabis operator IM Cannabis (CSE:IMCC) (NASDAQ:IMCC), which agreed to expand its product offering in Germany in 2021.

Photo by Diyahna Lewis on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

IM Cannabis, FLOWR Sign Multi-Year Deal To Import Medical Marijuana From Canada To Israel

Israel-based multi-country operator IM Cannabis (CSE: IMCC) (NASDAQ: IMCC) announced it signed a three-year deal with Canadian licensed producer The FLOWR Corporation (OTC: FLWPF), under which the latter will provide its read more

MediPharm Labs Extends Collaboration With German Medical Cannabis Distributor ADREXpharma

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) will extend its supply deal with Europe-based medical cannabis company ADREXpharma GmbH. read more

The Flowr Corp. To Export Up To 500KG Of Medical Cannabis To Israel

The Flowr Corporation (OTCQX: FLWPF) will export up to 500 kilos of premium dry cannabis flower in bulk into Israel. The move follows the company's recent announcement that it had raised $15.9 million by selling units. read more

The Week In Cannabis: PA, MD, Big Tobacco, GTI, Sundial, MedMen, Earnings, Financings And More

Cannabis stocks traded mostly in the green this week, as we got into earnings season. read more